Browse > Article
http://dx.doi.org/10.3904/kjim.2014.29.3.370

Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin  

Lee, Tae-Hee (Department of Internal Medicine, Konyang University College of Medicine)
Lee, Kee-Ook (Department of Neurology, Konyang University College of Medicine)
Kim, Yong-Seok (Department of Internal Medicine, Konyang University College of Medicine)
Kim, Sun-Moon (Department of Internal Medicine, Konyang University College of Medicine)
Huh, Kyu-Chan (Department of Internal Medicine, Konyang University College of Medicine)
Choi, Young-Woo (Department of Internal Medicine, Konyang University College of Medicine)
Kang, Young-Woo (Department of Internal Medicine, Konyang University College of Medicine)
Publication Information
The Korean journal of internal medicine / v.29, no.3, 2014 , pp. 370-374 More about this Journal
Abstract
Various adverse events have been reported during combination therapy with pegylated (PEG)-interferon-$\alpha$ and ribavirin, although opportunistic infections, especially cryptococcal meningitis, are very rare. A 61-year-old woman complained of headaches and a fever during treatment of a chronic hepatitis C virus (HCV) infection. She had been treated for 7 months. Her headaches were refractory to analgesics, and she developed subtle nuchal rigidity. The cerebral spinal fluid (CSF) revealed a white blood cell count of $205/mm^3$, 51 mg/dL protein, 35 mg/dL glucose, and negative Cryptococcus antigen. The CSF culture resulted in no growth. Five days later, the CSF was positive for Cryptococcus antigen. We administered amphotericin B and flucytosine, followed by fluconazole. Approximately 2 months later, she was discharged. For the first time, we report a case of cryptococcal meningitis during the treatment of chronic HCV with PEG-interferon-$\alpha$ and ribavirin.
Keywords
Cryptococcus; Meningitis; PEG-interferon-${\alpha}$; Ribavirin; Hepatitis C;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Erickson S, Matikainen S, Thyrell L, et al. Interferon- alpha inhibits Stat5 DNA-binding in IL-2 stimulated primary T-lymphocytes. Eur J Biochem 2002;269:29-37.   DOI   ScienceOn
2 Byrnes AA, Ma X, Cuomo P, et al. Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunity. Eur J Immunol 2001;31:2026-2034.   DOI
3 Lombardi G, Dunne PJ, Scheel-Toellner D, et al. Type 1 IFN maintains the survival of anergic CD4+ T cells. J Immunol 2000;165:3782-3789.   DOI
4 Bani-Sadr F, Goderel I, Lapidus N, et al. Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. AIDS 2008;22:1385-1387.   DOI   ScienceOn
5 Shih CC, Chen YC, Chang SC, Luh KT, Hsieh WC. Cryptococcal meningitis in non-HIV-infected patients. QJM 2000;93:245-251.   DOI   ScienceOn
6 Kauffman CA. Cryptococcosis. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia: Saunders, 2008:2347-2349.
7 Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998;79:2381-2391.   DOI
8 Shiffman ML, Verbeke SB, Kimball PM. Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes. Antiviral Res 2000;48:91-99.   DOI   ScienceOn
9 Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(5 Suppl 1):S237-S244.
10 Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36:1273-1279.   DOI   ScienceOn
11 Cooper CL, Al-Bedwawi S, Lee C, Garber G. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006;42:1674-1678.   DOI   ScienceOn
12 Juarez-Navarro A, Vera-de-Leon L, Navarro JM, et al. Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection. Methods Find Exp Clin Pharmacol 2005;27:317-322.   DOI   ScienceOn
13 Puoti M, Babudieri S, Rezza G, et al. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir Ther 2004;9:627-630.
14 Antonini MG, Babudieri S, Maida I, et al. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection 2008;36:250-255.   DOI   ScienceOn
15 Kwon-Chung KJ, Sorrell TC, Dromer F, Fung E, Levitz SM. Cryptococcosis: clinical and biological aspects. Med Mycol 2000;38 Suppl 1:205-213.   DOI   ScienceOn
16 Netea MG, Brouwer AE, Hoogendoorn EH, et al. Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon-gamma therapy. Clin Infect Dis 2004;39:e83-e87.   DOI   ScienceOn
17 Vander T, Medvedovsky M, Hallevy C, Golzman G, Herishanu Y. Listeria monocytogenes meningitis in a patient with chronic hepatitis C infection, treated by interferon alfa and ribavirin. J Infect 2003;46:70-71.   DOI   ScienceOn
18 Hadem J, Cornberg M, Hauptmann C, Suttmann U, Manns MP, Wedemeyer H. Pneumococcal meningitis during antiviral treatment with interferon and ribavirin in a splenectomized patient with chronic hepatitis C: do not miss vaccination before starting therapy. Z Gastroenterol 2008;46:880-882.   DOI   ScienceOn
19 Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444-2451.   DOI   ScienceOn
20 Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A 1994;91:1198-1205.   DOI   ScienceOn
21 Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990;12:1139-1146.   DOI